In Brief This Week: Transgenomic; Fluxion Biosciences; Silicon Biosystems; DNA Genotek; Annai Systems | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic said in a document filed with the US Securities and Exchange Commission this week that its shareholders have approved an increase in the number of authorized shares of the firm's common stock from 100 million to 150 million.

Fluxion Biosciences said this week that it has launched its discovery services business, which will offer a range of cellular assays in ion channels using its IonFlux system, functional cell analysis using its BioFlux system, and circulating tumor cell analysis using its IsoFlux platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.